As sirtuin activators, both resveratrol and piceatannol could upregulate the expression of PD-L1 though HDAC3/p300-mediated NF-κB signaling in breast and colon cancer cells, which combined with anti-PD-L1 immunotherapy may reap clinical benefits in no or low PD-L1 level cancer patients [159]. This evidence concerns the gene CD274 and colonic neoplasm.